Medscape March 14, 2024
New data continued to show clinical benefits from continuous glucose monitoring (CGM) in people with type 2 diabetes, including those who don’t use insulin.
Use of CGM is now considered standard of care for people with type 1 diabetes. Use in type 2 diabetes is growing among those who use insulin, for whom the devices are covered by Medicare and increasingly by other payers. Yet, overall use in type 2 diabetes remains low.
New data from multiple studies presented at the Advanced Technologies & Treatments for Diabetes (ATTD) meeting held in Florence, Italy, on March 6-9, 2024, demonstrated improved glycemic control and other cardiometabolic measures, reduced healthcare resource utilization, and reduced mortality among people with type 2 diabetes who use...
Today's Sponsors
Today's Sponsor